Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

ORKA

Oruka Therapeutics Inc

May 22 • 04:00PM ET

60.61

+1.92 3.27 %

Healthcare • Biotechnology • USA • Mid • NASD

Peers: MLTX KRYS ARQT KYMR VERA

| Held by: VTI IWM XBI VXF IWN IBB VTWO SCHA IWC VHT

Index	RUT	P/E	-	EPS (ttm)	-2.39	Insider Own	16.61%	Shs Outstand	60.31M	Perf Week	-2.13%
Market Cap	3.66B	Forward P/E	-	EPS next Y	-2.49	Insider Trans	-1.81%	Shs Float	50.29M	Perf Month	-10.53%
Enterprise Value	3.27B	PEG	-	EPS next Q	-0.51	Inst Own	76.52%	Short Float	13.90%	Perf Quarter	81.90%
Income	-116.25M	P/S	-	EPS this Y	-14.11%	Inst Trans	14.13%	Short Ratio	4.99	Perf Half Y	114.47%
Sales	0.00M	P/B	6.29	EPS next Y	-18.03%	ROA	-26.37%	Short Interest	6.99M	Perf YTD	99.97%
Book/sh	9.64	P/C	9.40	EPS next 5Y	-22.30%	ROE	-27.31%	52W High	91.00 -33.40%	Perf Year	441.64%
Cash/sh	6.45	P/FCF	-	EPS past 3/5Y	34.61% 37.79%	ROIC	-23.83%	52W Low	10.64 469.91%	Perf 3Y	345.08%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.46% 7.80%	Perf 5Y	182.02%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	54.61%	Oper. Margin	-	ATR (14)	4.25	Perf 10Y	-85.09%
Dividend Ex-Date	-	Quick Ratio	23.76	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	47.51	Recom	1.07
Dividend Gr. 3/5Y	- -	Current Ratio	23.76	EPS Q/Q	-14.47%	SMA20	-6.64%	Beta	-0.21	Target Price	141.31
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	3.43%	Rel Volume	0.66	Prev Close	58.69
Employees	68	LT Debt/Eq	0.00	Earnings	May 13 AMC	SMA200	76.53%	Avg Volume	1.40M	Price	60.61
IPO	Aug 08, 1997	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.23% -	Trades		Volume	928,470	Change	3.27%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-18-25	Initiated	Piper Sandler	Overweight	$75
Nov-13-25	Initiated	Jefferies	Buy	$45
Oct-27-25	Initiated	Guggenheim	Buy	$60
Oct-13-25	Initiated	Barclays	Overweight	$48
May-22-25	Initiated	BTIG Research	Buy	$44
Feb-04-25	Initiated	Wolfe Research	Outperform	$20
Oct-11-24	Initiated	Stifel	Buy	$49
Oct-07-24	Initiated	H.C. Wainwright	Buy	$45
Sep-17-24	Initiated	Leerink Partners	Outperform	$44
Sep-16-24	Initiated	TD Cowen	Buy
Sep-13-24	Initiated	Jefferies	Buy	$40
Feb-27-18	Initiated	Ascendiant Capital Markets	Buy	$2
Oct-09-13	Initiated	Dawson James	Buy	$3.75

Show Previous Ratings

May-13-26 04:03PM	Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-07-26 05:07AM	Halozyme and Oruka sign agreement for Hypercon technology (Pharmaceutical Technology) -8.20%
Apr-28-26 07:42PM	Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering (GlobeNewswire) -7.96%
Apr-27-26 04:17PM	Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering (GlobeNewswire) +10.66%
10:24AM	Oruka Therapeutics psoriasis drug clears skin in 64% of patients (Quartz)
09:49AM	Loading…
09:49AM	Oruka Therapeutics Shares Jump on Strong Psoriasis Trial Results (InvestorsHub)
08:12AM	Oruka surges as long-acting psoriasis drug shows early promise (BioPharma Dive)
07:01AM	How A Small Biotech Name Just Rattled AbbVie's $18 Billion Franchise (Investor's Business Daily)
07:00AM	Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis (GlobeNewswire)
Apr-26-26 12:00PM	Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026 (GlobeNewswire)
Apr-10-26 05:28PM	This Startup's Psoriasis Drug Studies Have Lifted Its Stock (Barrons.com) -6.32%
Mar-12-26 04:05PM	Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -7.03% +25.04%
Feb-09-26 07:00AM	Oruka Therapeutics to Participate in Multiple Upcoming Conferences (GlobeNewswire)
Jan-12-26 07:00AM	Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001 (GlobeNewswire) +10.16%
Jan-06-26 07:00AM	Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
04:01PM	Loading…
Dec-11-25 04:01PM	Oruka Therapeutics Announces New Board Member and Board Transition (GlobeNewswire)
Nov-12-25 04:05PM	Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -6.78%
Oct-29-25 09:55AM	Wall Street Analysts Predict a 63.59% Upside in Oruka Therapeutics, Inc. (ORKA): Here's What You Should Know (Zacks)
07:00AM	Oruka Therapeutics to Present at Multiple November Investor Conferences (GlobeNewswire)
Oct-13-25 05:52AM	Barclays initiates coverage on U.S. small & mid-cap biotech stocks (Investing.com)
Sep-29-25 04:24PM	MoonLake Crashes 90% On Mixed Results For Skin Disease Treatment (Investor's Business Daily) +26.91%
Sep-17-25 04:11PM	Oruka Therapeutics, Up 9%, Is Trying To Take On AbbVie's Biggest Moneymaker (Investor's Business Daily) +8.79%
01:02AM	Oruka Therapeutics Announces $180 Million Private Placement (GlobeNewswire)
01:00AM	Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001 (GlobeNewswire)
Aug-11-25 04:04PM	Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +6.90%
Jul-21-25 07:00AM	Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September (GlobeNewswire) -5.30%
Jul-01-25 04:01PM	Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer (GlobeNewswire) +5.26% +6.86%
May-27-25 03:32PM	H.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 Trial (Insider Monkey)
May-21-25 07:00AM	Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-25 04:01PM	Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody (GlobeNewswire)
04:15PM	Loading…
May-14-25 04:15PM	Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-29-25 07:00AM	Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference (GlobeNewswire)
Mar-07-25 08:30AM	Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-06-25 04:09PM	Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-19-25 07:00AM	Oruka Therapeutics to Present at Multiple March Investor Conferences (GlobeNewswire)
Dec-20-24 07:15AM	Oruka Therapeutics doses first participants in Phase 1 trial of ORKA-001 (TipRanks)
Dec-19-24 07:00AM	Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody (GlobeNewswire)
Dec-18-24 07:00AM	Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI) (GlobeNewswire)
Nov-19-24 08:00AM	Oruka Therapeutics to Present at Piper Sandler's 36th Annual Healthcare Conference (GlobeNewswire) +5.54%
Nov-13-24 04:25PM	Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -6.43%
Nov-04-24 07:00AM	Oruka Therapeutics to Present at Multiple November Investor Conferences (GlobeNewswire)
Sep-25-24 07:08AM	Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress (GlobeNewswire)
Sep-12-24 07:05AM	Oruka Therapeutics Announces $200 Million Private Placement (GlobeNewswire) -12.22%
07:00AM	Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001's Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19 (GlobeNewswire)
Sep-03-24 07:00AM	Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million (GlobeNewswire) -11.46%
Aug-29-24 04:50PM	ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split (GlobeNewswire) +33.19%
Aug-26-24 07:30PM	ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics (GlobeNewswire) -8.41%
Aug-23-24 04:30PM	ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics (GlobeNewswire) +6.12%
Aug-16-24 04:15PM	ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics (GlobeNewswire) +21.36%
Aug-01-24 04:15PM	ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +5.07%
Jun-28-24 02:16AM	Why Are Hedge Funds Shorting ARCA Biopharma, Inc. (ABIO)? (Insider Monkey) +6.39%
Jun-26-24 11:08PM	What Is Short Selling In Stock Market? 15 Stocks Hedge Funds are Shorting (Insider Monkey)
May-14-24 01:48PM	3 Short-Squeeze Stocks Ready to Soar on Roaring Kitty Rally (InvestorPlace)
Apr-25-24 09:55PM	ABIO Stock Earnings: ARCA biopharma Reported Results for Q1 2024 (InvestorPlace)
04:15PM	ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-03-24 02:30PM	Why Is ARCA Biopharma (ABIO) Stock Up 85% Today? (InvestorPlace) +90.06%
12:00PM	Small-Cap ARCA Biopharma Stock Soars On Merger Pact: The Details (Benzinga)
07:30AM	ARCA biopharma and Oruka Therapeutics Announce Merger Agreement (GlobeNewswire)
Feb-01-24 04:35PM	ARCA biopharma Announces 2023 Financial Results (GlobeNewswire)
Oct-18-23 04:25PM	ARCA biopharma Announces Third Quarter 2023 Financial Results (GlobeNewswire)
Jul-21-23 04:25PM	ARCA biopharma Announces Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-13-23 11:30AM	We're Not Very Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Rate (Simply Wall St.)
Apr-24-23 04:25PM	ARCA biopharma Announces First Quarter 2023 Financial Results (GlobeNewswire)
Feb-24-23 04:20PM	ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-03-23 10:19AM	Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation (Simply Wall St.)
Dec-19-22 04:05PM	James Flynn Joins ARCA biopharma Board of Directors (GlobeNewswire)
Nov-14-22 09:24AM	One ARCA biopharma, Inc. (NASDAQ:ABIO) insider upped their stake by 5,155% in the previous year (Simply Wall St.)
Oct-28-22 04:15PM	ARCA biopharma Announces Third Quarter 2022 Financial Results (GlobeNewswire)
Aug-02-22 04:15PM	ARCA biopharma Announces Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-18-22 06:14AM	Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jun-21-22 04:05PM	Jacob Ma-Weaver Joins ARCA biopharma Board of Directors (GlobeNewswire) +5.56%
May-05-22 04:15PM	ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review (GlobeNewswire) -5.79%
May-02-22 04:15PM	ARCA biopharma Announces First Quarter 2022 Financial Results (GlobeNewswire)
Apr-18-22 04:30PM	ARCA biopharma Establishes Special Committee of the Board of Directors (GlobeNewswire)
Apr-05-22 01:35AM	Albioma : Governance changes (GlobeNewswire)
Apr-01-22 07:09AM	ARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study (Benzinga)
Mar-31-22 04:15PM	ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial (GlobeNewswire)
Mar-14-22 04:15PM	ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-07-22 04:30PM	Battalion Oil Corporation Announces Fourth Quarter and Full Year 2021 Financial and Operating Results (GlobeNewswire)
Feb-08-22 04:21AM	We're Keeping An Eye On ARCA biopharma's (NASDAQ:ABIO) Cash Burn Rate (Simply Wall St.)
Jan-04-22 08:30AM	Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2 (GlobeNewswire)
Dec-02-21 08:30AM	ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19 (GlobeNewswire)
Nov-20-21 07:01AM	ClearPoint Neuro (NASDAQ:CLPT) shareholders are still up 635% over 3 years despite pulling back 13% in the past week (Simply Wall St.)
Nov-09-21 04:15PM	ARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17th (GlobeNewswire)
Nov-02-21 04:15PM	ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-29-21 07:03AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
06:26AM	ARCA Biopharma Stock Gains As Safety Committee Recommends COVID-19 Trial To Continue Unchanged (Benzinga)
Oct-28-21 04:30PM	ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completion Based on Interim Analysis of Efficacy and Safety Data (GlobeNewswire)
Sep-16-21 08:30AM	ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19 (GlobeNewswire)
Aug-16-21 08:05AM	ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th (GlobeNewswire) -5.14%
Aug-12-21 01:15AM	We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth (Simply Wall St.)
Aug-09-21 08:00AM	ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2 (GlobeNewswire)
Aug-04-21 04:15PM	ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire) +5.44%
Jul-28-21 08:00AM	Gencaro Atrial Fibrillation Phase 2B Results Selected for Publication in Circulation: Arrhythmia and Electrophysiology (GlobeNewswire)
Jul-13-21 08:00AM	ARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19 (GlobeNewswire) -14.09%
Jul-09-21 08:00AM	ARCA biopharma to Present at Access to Giving Virtual Investor Conference on July 13th (GlobeNewswire) +5.75%
Jul-08-21 11:20AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE) -6.95%
Jul-07-21 08:00AM	ARCA biopharma Announces rNAPc2 COVID-19 Patent Assignment Agreement (GlobeNewswire) +9.36%
Jun-23-21 09:35AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE)
May-11-21 04:15PM	ARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

PresidentDr. Lawrence Otto Klein Ph.D.

General Counsel & SecretaryMr. Paul T. Quinlan

Chief Medical OfficerDr. Joana Goncalves M.D.

Senior VP of Finance & TreasurerMr. Arjun Agarwal CPA

Chief Operating OfficerMs. Laura Sandler

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dambkowski Carl	Director	May 21 '26	Option Exercise	7.95	62,260	494,805	178,743	May 22 04:54 PM
Dambkowski Carl	Director	May 21 '26	Sale	58.97	105,000	6,191,366	73,743	May 22 04:54 PM
CARL DAMBKOWSKI	Director	May 21 '26	Proposed Sale	60.67	105,000	6,370,350		May 21 04:32 PM
Agarwal Arjun	Senior Vice President, Finance	May 18 '26	Option Exercise	28.80	7,833	225,597	26,696	May 18 06:07 PM
Agarwal Arjun	Senior Vice President, Finance	May 18 '26	Sale	59.07	10,290	607,806	16,406	May 18 06:07 PM
ARJUN AGARWAL	Officer	May 18 '26	Proposed Sale	61.93	22,206	1,375,218		May 18 04:34 PM
Goncalves Joana	Chief Medical Officer	May 15 '26	Option Exercise	7.32	7,000	51,240	40,377	May 15 08:17 PM
Goncalves Joana	Chief Medical Officer	May 15 '26	Sale	61.85	7,000	432,935	33,377	May 15 08:17 PM
Sandler Laura Lee	Chief Operating Officer	May 01 '26	Option Exercise	7.80	5,000	39,000	241,984	May 01 06:25 PM
Sandler Laura Lee	Chief Operating Officer	May 01 '26	Sale	63.88	5,000	319,384	236,984	May 01 06:25 PM
LAURA SANDLER	Officer	May 01 '26	Proposed Sale	68.41	10,000	684,100		May 01 04:42 PM
Goncalves Joana	Chief Medical Officer	Apr 15 '26	Option Exercise	7.32	7,000	51,240	40,377	Apr 15 06:45 PM
Goncalves Joana	Chief Medical Officer	Apr 15 '26	Sale	66.12	7,000	462,830	33,377	Apr 15 06:45 PM
JOANA GONCALVES	Officer	Apr 15 '26	Proposed Sale	67.06	21,000	1,408,260		Apr 15 04:54 PM
Klein Lawrence Otto	Chief Executive Officer	Mar 16 '26	Sale	41.30	1,729	71,408	927,309	Mar 17 04:10 PM
Agarwal Arjun	Senior Vice President, Finance	Mar 16 '26	Sale	41.30	395	16,313	18,863	Mar 17 04:09 PM
Sandler Laura Lee	Chief Operating Officer	Mar 16 '26	Sale	41.30	600	24,780	236,984	Mar 17 04:08 PM
Goncalves Joana	Chief Medical Officer	Mar 16 '26	Option Exercise	7.32	7,000	51,240	41,018	Mar 17 04:06 PM
Goncalves Joana	Chief Medical Officer	Mar 16 '26	Sale	40.91	7,641	312,560	33,377	Mar 17 04:06 PM
Quinlan Paul T	General Counsel	Mar 16 '26	Sale	41.30	733	30,273	31,767	Mar 17 04:04 PM
Sandler Laura Lee	Chief Operating Officer	Mar 02 '26	Option Exercise	7.80	5,000	39,000	242,584	Mar 02 06:47 PM
Sandler Laura Lee	Chief Operating Officer	Mar 02 '26	Sale	33.56	5,000	167,822	237,584	Mar 02 06:47 PM
Goncalves Joana	Chief Medical Officer	Feb 17 '26	Option Exercise	7.32	7,000	51,240	41,018	Feb 17 05:24 PM
Goncalves Joana	Chief Medical Officer	Feb 17 '26	Sale	32.37	7,000	226,559	34,018	Feb 17 05:24 PM
Goncalves Joana	Chief Medical Officer	Jan 15 '26	Option Exercise	7.32	7,000	51,240	8,518	Jan 16 05:26 PM
Goncalves Joana	Chief Medical Officer	Jan 15 '26	Sale	31.81	7,000	222,704	1,518	Jan 16 05:26 PM
Sandler Laura Lee	Chief Operating Officer	Jan 02 '26	Option Exercise	7.80	5,000	39,000	218,084	Jan 02 08:25 PM
Sandler Laura Lee	Chief Operating Officer	Jan 02 '26	Sale	28.52	13,000	370,795	205,084	Jan 02 08:25 PM
LAURA SANDLER	Officer	Jan 02 '26	Proposed Sale	30.31	18,000	545,580		Jan 02 04:31 PM
Goncalves Joana	Chief Medical Officer	Dec 19 '25	Option Exercise	7.32	7,000	51,240	8,518	Dec 19 05:38 PM
Goncalves Joana	Chief Medical Officer	Dec 19 '25	Sale	30.61	7,000	214,293	1,518	Dec 19 05:38 PM
JOANA GONCALVES	Officer	Dec 19 '25	Proposed Sale	28.15	28,000	788,200		Dec 19 04:20 PM

Open in Screener

APGE

Apogee Therapeutics Inc

May 22 • 04:00PM ET

81.16

-1.27 -1.54 %

Healthcare • Biotechnology • USA • Mid • NASD

APGE Apogee Therapeutics Inc daily Stock Chart

Peers: ARQT ANAB KYMR NRIX IMVT

| Held by: VTI XBI IWM TCAF VXF IWO IBB SCHA VTWO VHT

Index	RUT	P/E	-	EPS (ttm)	-4.33	Insider Own	24.46%	Shs Outstand	61.40M	Perf Week	0.02%
Market Cap	6.11B	Forward P/E	-	EPS next Y	-5.36	Insider Trans	-9.73%	Shs Float	56.91M	Perf Month	-8.08%
Enterprise Value	5.06B	PEG	-	EPS next Q	-1.08	Inst Own	92.79%	Short Float	16.67%	Perf Quarter	16.09%
Income	-274.62M	P/S	-	EPS this Y	-6.57%	Inst Trans	23.43%	Short Ratio	10.83	Perf Half Y	27.15%
Sales	0.00M	P/B	4.84	EPS next Y	-19.19%	ROA	-27.35%	Short Interest	9.49M	Perf YTD	7.53%
Book/sh	16.77	P/C	5.77	EPS next 5Y	-14.63%	ROE	-28.47%	52W High	95.32 -14.85%	Perf Year	101.09%
Cash/sh	14.07	P/FCF	-	EPS past 3/5Y	-75.11% -	ROIC	-21.78%	52W Low	34.34 136.34%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.58% 4.79%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-22.17%	Oper. Margin	-	ATR (14)	4.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	32.59	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	46.58	Recom	1.24
Dividend Gr. 3/5Y	- -	Current Ratio	32.59	EPS Q/Q	-11.87%	SMA20	-1.76%	Beta	0.66	Target Price	119.69
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-1.07%	Rel Volume	0.39	Prev Close	82.43
Employees	261	LT Debt/Eq	0.00	Earnings	May 11 BMO	SMA200	24.68%	Avg Volume	876.55K	Price	81.16
IPO	Jul 14, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.97% -	Trades		Volume	338,435	Change	-1.54%

Date	Action	Analyst	Rating Change	Price Target Change
May-01-26	Initiated	Rothschild & Co Redburn	Buy	$140
Mar-18-26	Initiated	Truist	Hold	$83
Jan-22-26	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$83
Jan-07-26	Initiated	Wolfe Research	Peer Perform
Dec-17-25	Initiated	Stephens	Overweight	$95
Dec-10-25	Initiated	Deutsche Bank	Buy	$103
Nov-03-25	Initiated	Craig Hallum	Buy	$109
Oct-21-25	Initiated	Mizuho	Outperform	$105
Sep-25-25	Initiated	RBC Capital Mkts	Outperform	$60
Jul-07-25	Reiterated	BTIG Research	Buy	$100 → $115
Mar-13-25	Initiated	Citigroup	Buy	$95
Nov-25-24	Initiated	Canaccord Genuity	Buy	$89
May-10-24	Initiated	BofA Securities	Buy	$80
Dec-20-23	Initiated	BTIG Research	Buy	$43
Aug-08-23	Initiated	Wedbush	Outperform	$40
Aug-08-23	Initiated	TD Cowen	Outperform
Aug-08-23	Initiated	Stifel	Buy	$34
Aug-08-23	Initiated	Jefferies	Buy	$29
Aug-08-23	Initiated	Guggenheim	Buy	$29

Show Previous Ratings

May-11-26 07:00AM	Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results (GlobeNewswire)
Mar-26-26 04:01PM	Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million (GlobeNewswire)
Mar-24-26 09:53PM	Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering (GlobeNewswire) -7.87% +7.58%
Mar-23-26 04:01PM	Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering (GlobeNewswire) +19.99%
10:01AM	How Apogee, Up 14%, Plans To Take On Rival Regeneron's Eczema Drug (Investor's Business Daily)
08:15AM	Loading…
08:15AM	Apogee strengthens case for longer-lasting eczema drug (BioPharma Dive)
06:30AM	Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
Mar-22-26 07:51PM	Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026 (GlobeNewswire)
Mar-18-26 09:34AM	Block upgraded, Starbucks downgraded: Wall Street's top analyst calls (The Fly)
Mar-10-26 08:04AM	Wedbush Raises Price Target on Apogee Therapeutics (APGE) (Insider Monkey)
Mar-04-26 06:34AM	Apogee Therapeutics Teases 52-Week Zumi Durability Data, Phase III Path at TD Cowen Conference (MarketBeat) +5.56%
Mar-02-26 07:00AM	Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results (GlobeNewswire)
Feb-24-26 07:30AM	Apogee Therapeutics to Participate in Upcoming March Conferences (GlobeNewswire)
Feb-18-26 07:39PM	End of Apogee (APGE) Drug Collaboration Leads to Revised Analyst Expectations (Insider Monkey)
Feb-16-26 12:23PM	Here is Why Apogee Therapeutics (APGE) Appears Attractive (Insider Monkey)
09:07PM	Loading…
Feb-12-26 09:07PM	Apogee Therapeutics touts quarterly-to-biannual AD dosing shift, expands asthma ambitions at conference (MarketBeat) +5.32%
Feb-05-26 08:00AM	Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-30-26 07:39PM	Elastic NV, Acadia Healthcare, and More Stocks See Action From Activist Investors (Barrons.com) -6.39%
Jan-12-26 12:00PM	Funding for Risky Biotechs Is Returning (The Wall Street Journal)
Jan-07-26 09:41AM	Wayfair upgraded, Instacart initiated: Wall Street's top analyst calls (The Fly)
Jan-06-26 06:00AM	Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook (GlobeNewswire)
Jan-05-26 04:01PM	Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026 (GlobeNewswire)
Dec-09-25 12:19AM	Strong Pipeline and Analyst Confidence Push Apogee Therapeutics Inc. (APGE) Toward Growth (Insider Monkey)
Nov-11-25 09:40AM	Is Apogee Therapeutics Inc. (APGE) Outperforming Other Medical Stocks This Year? (Zacks) +10.89%
Nov-10-25 07:10AM	Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
07:00AM	Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody (GlobeNewswire)
Nov-03-25 07:30AM	Apogee Therapeutics to Participate in Upcoming Conferences (GlobeNewswire)
Oct-30-25 09:55AM	Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 69.3%: Here's is How to Trade (Zacks)
Oct-17-25 09:55PM	BTIG Maintains a Buy on Apogee Therapeutics (APGE) (Insider Monkey)
Oct-14-25 09:55AM	Does Apogee Therapeutics Inc. (APGE) Have the Potential to Rally 72.52% as Wall Street Analysts Expect? (Zacks)
04:01PM	Loading…
Oct-10-25 04:01PM	Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million (GlobeNewswire)
Oct-09-25 05:26PM	Why Apogee Therapeutics Stock Triumphed on Thursday (Motley Fool) +12.64%
01:08PM	Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out (Investor's Business Daily)
Oct-08-25 09:52PM	Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering (GlobeNewswire) +18.90%
04:01PM	Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering (GlobeNewswire)
Sep-30-25 04:00AM	RBC Capital Initiates Coverage of Apogee Therapeutics (APGE) With an Outperform Rating (Insider Monkey)
Sep-15-25 09:09AM	BofA Raises Apogee Therapeutics (APGE) PT to $87 Following Positive Phase 2 APEX Trial Results for Atopic Dermatitis (Insider Monkey)
Sep-11-25 07:30AM	Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress (GlobeNewswire)
Sep-03-25 07:30AM	Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum (GlobeNewswire)
Aug-11-25 07:00AM	Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-06-25 09:55AM	Wall Street Analysts See a 152.41% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High? (Zacks) -5.24%
Jul-31-25 11:38AM	Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug (Insider Monkey)
Jul-16-25 09:38AM	BTIG Raises PT on Apogee Therapeutics (APGE) to $115 From $100, Keeps a Buy Rating (Insider Monkey)
Jul-14-25 07:52AM	Canaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE) (Insider Monkey)
Jul-08-25 03:31PM	Regeneron's Blockbuster Dupixent Faces a New Rival (Barrons.com) -7.21%
02:26PM	Apogee Therapeutics (APGE) Falls 17%, Positive Trial Results Fail to Impress Investors (Insider Monkey)
Jul-07-25 04:27PM	Apogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker. (Investor's Business Daily) -17.32%
10:09AM	Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot (Investor's Business Daily)
06:00AM	Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
Jul-06-25 06:00PM	Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025 (GlobeNewswire)
04:01AM	Apogee Therapeutics Shares Positive Interim Phase 1b Results for APG808 in Asthma (Insider Monkey)
Jun-09-25 09:55AM	Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High? (Zacks)
May-29-25 07:30AM	Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-21-25 09:55AM	Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet (Zacks)
May-12-25 02:21PM	Why Is Apogee Therapeutics Stock Trading Higher On Monday? (Benzinga) +6.14%
06:05AM	Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results (GlobeNewswire)
06:00AM	Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody, in Patients with Mild-to-Moderate Asthma (GlobeNewswire)
06:00AM	Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4R Antibody, in Patients with Mild-to-Moderate Asthma (GlobeNewswire)
May-05-25 09:55AM	Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 134%: Here's is How to Trade (Zacks)
May-01-25 08:00AM	Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference (GlobeNewswire)
Apr-14-25 08:04AM	Apogee Therapeutics: Engineering Biologic Dominance (Seeking Alpha)
Mar-26-25 05:50PM	Is Apogee Therapeutics (APGE) Among the Best IPO Stocks to Buy in 2025? (InsiderMonkey)
Mar-03-25 12:16PM	Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial (Benzinga)
06:05AM	Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results (GlobeNewswire)
06:00AM	Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990) (GlobeNewswire)
Mar-01-25 09:22AM	Is Apogee Therapeutics, Inc. (APGE) the Best Small-Cap Stock to Buy Now? (Insider Monkey)
Feb-28-25 04:00PM	Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025 (GlobeNewswire)
Feb-25-25 07:30AM	Apogee Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-03-25 07:00AM	Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
Jan-30-25 03:44PM	Heres Why Apogee Therapeutics, Inc. (APGE) Will Double in 2025 (Insider Monkey) +5.41%
Jan-29-25 07:30AM	Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Dec-10-24 07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions (GlobeNewswire)
Dec-03-24 06:52AM	Apogee Therapeutics Advances in I&I Disease Treatments (TipRanks)
Dec-02-24 06:00AM	Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day (GlobeNewswire)
Nov-29-24 01:00PM	Apogee Therapeutics Announces Agenda for Virtual R&D Day (GlobeNewswire)
Nov-18-24 07:30AM	Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024 (GlobeNewswire)
Nov-13-24 07:21AM	Apogee reports Q3 EPS, expects cash to fund operations into Q1 of 2028 (TipRanks) -7.95%
Nov-12-24 07:00AM	Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results (GlobeNewswire) -5.14%
Nov-04-24 07:30AM	Apogee Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-24-24 08:00AM	Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire)
Oct-16-24 07:00AM	Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting (GlobeNewswire)
Oct-07-24 04:50PM	Apogee Therapeutics, Inc. (APGE): A Hot Stock to Buy Now (Insider Monkey)
Oct-04-24 01:03PM	Wellington Management Group LLP Increases Stake in Apogee Therapeutics Inc (GuruFocus.com)
Sep-12-24 07:00AM	Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit (GlobeNewswire)
Sep-09-24 07:00AM	Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer (GlobeNewswire)
Sep-07-24 01:45AM	Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
Aug-24-24 01:30AM	Insider Sale: CFO Jane Henderson Sells 6,000 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
Aug-19-24 07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire) +10.59%
Aug-12-24 06:30AM	Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results (GlobeNewswire) +9.78%
Aug-10-24 01:00AM	Apogee Therapeutics Inc (APGE) CEO Michael Henderson Sells 40,000 Shares (GuruFocus.com)
01:00AM	Insider Sale: Carl Dambkowski Sells 7,335 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
Jul-18-24 08:00AM	NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors (GlobeNewswire)
Jul-06-24 01:00AM	Insider Sale: CEO Michael Henderson Sells 15,000 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
01:00AM	Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
May-28-24 07:30AM	Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD (GlobeNewswire)
May-23-24 07:30AM	Apogee Therapeutics to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-15-24 04:01PM	Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire)
May-13-24 01:53PM	APGE Stock Earnings: Apogee Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:42AM	Apogee Therapeutics' Q1 Net Loss Widens (MT Newswires)
07:00AM	Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results (GlobeNewswire)

Apogee Therapeutics, Inc. is a clinical stage biotechnology company. It offers treatment of atopic dermatitis (AD), ashma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded by Andrew Gottesdiener and Nimish P. Shah in 2022 and is headquartered in Waltham, MA.

CEO & DirectorDr. Michael Thomas Henderson M.D.

Chief Financial OfficerMs. Jane Pritchett V. Henderson

Chief Medical OfficerDr. Carl Linden Dambkowski M.D.

Vice President of Investor RelationsMs. Noel Kurdi

Chief Legal Officer & Corporate SecretaryMr. Matthew Batters J.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HENDERSON MICHAEL THOMAS	Chief Executive Officer	May 13 '26	Sale	82.09	20,000	1,641,711	1,115,987	May 15 08:00 PM
HENDERSON MICHAEL THOMAS	Officer	May 13 '26	Proposed Sale	82.47	60,000	4,948,200		May 13 10:34 AM
Dambkowski Carl	Chief Medical Officer	May 06 '26	Option Exercise	22.86	4,125	94,298	212,523	May 08 08:00 PM
Dambkowski Carl	Chief Medical Officer	May 06 '26	Sale	84.14	5,500	462,784	207,023	May 08 08:00 PM
CARL DAMBKOWSKI	Officer	May 06 '26	Proposed Sale	83.29	22,000	1,832,380		May 06 04:25 PM
Henderson Jane	Chief Financial Officer	May 01 '26	Sale	82.04	2,000	164,080	173,371	May 04 08:00 PM
JANE HENDERSON	Officer	May 01 '26	Proposed Sale	82.89	2,000	165,780		May 01 04:45 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Apr 16 '26	Option Exercise	22.86	3,000	68,580	1,135,987	Apr 20 04:05 PM
Henderson Jane	Chief Financial Officer	Apr 16 '26	Sale	90.00	2,000	180,000	175,371	Apr 17 08:00 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Apr 08 '26	Sale	82.58	20,000	1,651,664	1,132,987	Apr 10 08:00 PM
Dambkowski Carl	Chief Medical Officer	Apr 01 '26	Option Exercise	22.86	4,125	94,298	213,898	Apr 03 08:00 PM
Dambkowski Carl	Chief Medical Officer	Apr 01 '26	Sale	84.84	5,500	466,619	208,398	Apr 03 08:00 PM
Henderson Jane	Chief Financial Officer	Apr 01 '26	Sale	85.01	2,000	170,020	177,371	Apr 03 08:00 PM
Henderson Jane	Chief Financial Officer	Mar 25 '26	Sale	85.00	2,000	170,000	179,371	Mar 27 08:00 PM
JANE HENDERSON	Officer	Mar 25 '26	Proposed Sale	73.00	6,000	438,000		Mar 25 04:24 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Mar 11 '26	Sale	74.78	20,000	1,495,605	1,152,987	Mar 13 08:00 PM
Dambkowski Carl	Chief Medical Officer	Mar 04 '26	Option Exercise	22.86	4,125	94,298	215,273	Mar 06 08:00 PM
Dambkowski Carl	Chief Medical Officer	Mar 04 '26	Sale	71.06	5,500	390,825	209,773	Mar 06 08:00 PM
Henderson Jane	Chief Financial Officer	Mar 02 '26	Sale	70.22	2,000	140,431	181,371	Mar 04 08:00 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Feb 11 '26	Sale	63.35	20,000	1,266,953	1,172,987	Feb 13 08:00 PM
HENDERSON MICHAEL THOMAS	Officer	Feb 11 '26	Proposed Sale	64.00	60,000	3,840,000		Feb 11 10:42 AM
Dambkowski Carl	Chief Medical Officer	Feb 04 '26	Option Exercise	22.86	4,125	94,298	216,648	Feb 04 08:02 PM
Dambkowski Carl	Chief Medical Officer	Feb 04 '26	Sale	65.79	5,500	361,860	211,148	Feb 04 08:02 PM
Henderson Jane	Chief Financial Officer	Feb 02 '26	Sale	65.81	2,000	131,630	183,371	Feb 04 08:01 PM
Fairmount Funds Management LLC	Director	Jan 22 '26	Sale	76.30	1,750,000	133,525,000	298,647	Jan 22 08:07 PM
Fairmount Healthcare Fund II L	Director	Jan 22 '26	Proposed Sale	76.30	1,750,000	133,525,000		Jan 22 08:03 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Jan 14 '26	Sale	81.11	20,000	1,622,159	1,192,987	Jan 16 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jan 07 '26	Option Exercise	22.86	14,025	320,612	231,223	Jan 09 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jan 07 '26	Sale	77.84	18,700	1,455,613	212,523	Jan 09 08:00 PM
CARL DAMBKOWSKI	Officer	Jan 07 '26	Proposed Sale	78.25	35,200	2,754,400		Jan 07 04:27 PM
Henderson Jane	Chief Financial Officer	Jan 02 '26	Sale	74.86	6,000	449,146	187,371	Jan 06 08:00 PM
Henderson Jane	Chief Financial Officer	Jan 06 '26	Sale	80.00	2,000	160,000	185,371	Jan 06 08:00 PM
JANE HENDERSON	Officer	Jan 02 '26	Proposed Sale	75.48	12,000	905,760		Jan 02 04:31 PM
Henderson Jane	Chief Financial Officer	Dec 19 '25	Sale	80.00	1,500	120,000	193,371	Dec 23 08:00 PM
JANE HENDERSON	Officer	Dec 19 '25	Proposed Sale	77.35	1,500	116,025		Dec 19 04:24 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Dec 10 '25	Sale	75.38	20,000	1,507,657	1,212,987	Dec 12 08:00 PM
Dambkowski Carl	Chief Medical Officer	Dec 04 '25	Sale	75.00	10,900	817,500	271,108	Dec 05 08:03 PM
Henderson Jane	Chief Financial Officer	Dec 04 '25	Sale	75.00	1,500	112,500	194,871	Dec 05 08:02 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Dec 04 '25	Sale	75.01	40,000	3,000,400	1,232,987	Dec 05 08:00 PM
JANE HENDERSON	Officer	Dec 04 '25	Proposed Sale	74.55	1,500	111,825		Dec 04 04:43 PM
CARL DAMBKOWSKI	Officer	Dec 04 '25	Proposed Sale	74.55	10,900	812,595		Dec 04 04:41 PM
Henderson Jane	Chief Financial Officer	Nov 25 '25	Sale	70.00	1,500	105,000	196,371	Nov 28 08:00 PM
JANE HENDERSON	Officer	Nov 25 '25	Proposed Sale	67.85	1,500	101,775		Nov 25 04:28 PM
Henderson Jane	Chief Financial Officer	Nov 14 '25	Sale	65.00	2,000	130,000	197,871	Nov 14 08:00 PM
JANE HENDERSON	Officer	Nov 14 '25	Proposed Sale	62.97	2,000	125,940		Nov 14 04:31 PM
Henderson Jane	Chief Financial Officer	Nov 11 '25	Sale	60.00	1,000	60,000	199,871	Nov 13 08:37 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Nov 13 '25	Sale	63.01	20,000	1,260,236	1,272,987	Nov 13 08:24 PM
HENDERSON MICHAEL THOMAS	Officer	Nov 13 '25	Proposed Sale	66.98	100,000	6,697,800		Nov 13 10:33 AM
JANE HENDERSON	Officer	Nov 11 '25	Proposed Sale	56.77	1,000	56,770		Nov 12 07:03 AM
Dambkowski Carl	Chief Medical Officer	Nov 05 '25	Option Exercise	22.86	8,060	184,252	292,793	Nov 07 08:00 PM
Dambkowski Carl	Chief Medical Officer	Nov 05 '25	Sale	55.07	10,785	593,903	282,008	Nov 07 08:00 PM
CARL DAMBKOWSKI	Officer	Nov 05 '25	Proposed Sale	53.90	10,785	581,312		Nov 05 04:17 PM
Dambkowski Carl	Chief Medical Officer	Oct 01 '25	Option Exercise	22.86	2,385	54,521	289,843	Oct 03 08:00 PM
Dambkowski Carl	Chief Medical Officer	Oct 01 '25	Sale	39.80	5,110	203,378	284,733	Oct 03 08:00 PM
Dambkowski Carl	Chief Medical Officer	Sep 03 '25	Sale	37.87	2,725	103,198	233,548	Sep 05 08:00 PM
Dambkowski Carl	Chief Medical Officer	Aug 06 '25	Sale	37.78	2,725	102,950	236,273	Aug 08 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jul 02 '25	Option Exercise	22.86	7,365	168,364	249,088	Jul 03 08:00 PM
Dambkowski Carl	Chief Medical Officer	Jul 02 '25	Sale	45.09	10,090	454,954	238,998	Jul 03 08:00 PM
CARL DAMBKOWSKI	Officer	Jul 02 '25	Proposed Sale	44.26	22,345	988,990		Jul 02 04:22 PM
Dambkowski Carl	Chief Medical Officer	Jun 04 '25	Sale	36.96	2,725	100,716	241,723	Jun 06 08:01 PM

ORKA

Oruka Therapeutics Inc

APGE

Apogee Therapeutics Inc

Upgrade your Finviz experience